GlassScriptPhysician profile
Richard P Stankus
NPI 1023119021
$4,906.95
in general payments reported to CMS, 2019-2025
19 companies · $726 in 2025
The $726 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $233 · 2021: $626 · 2022: $693 · 2023: $1,253 · 2024: $987 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,911 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.34 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,956.07 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Novartis Pharmaceuticals Corporation | $810.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $546.68 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $419.82 | 2019-2025 | |
| Genentech USA, INC. | $201.53 | 2019-2025 | Xolair |
| Amgen INC. | $200.68 | 2021-2025 | Tezspire |
| Pfizer INC. | $155.72 | 2020-2023 | |
| Biocryst US Sales Co., LLC | $121.32 | 2023-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.33 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $61.25 | 2021-2025 | Takhzyro |
| Alk-Abello, INC | $60.53 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Regeneron Healthcare Solutions, INC. | $56.53 | 2020-2023 | Dupixent |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Kaleo, INC. | $43.46 | 2022-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $36.76 | 2025 | Neffy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $34.36 | 2024 | Hizentra |
| Uswm, LLC | $22.24 | 2021 | |
| Merck Sharp & Dohme LLC | $15.05 | 2023 | |
| Mylan Specialty L.P. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Stankus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.